Gram-positive bacterial infection in severe sepsis

References

• McGowan JE. Increasing threat of Gram-positive bacterial infections in the intensive care unit setting. Crit. Care Med. 2001; 29(4): N 69–N 74.
   Google Scholar
• Tanowitz H B, Chan J. Gram-positive sepsis. Crit. Care Med. 2000; 28(8): 3081–3082.
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C, Doyon F, Carlet J. Bacteraemia and severe sepsis in adults: A multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteraemia-Sepsis Study Group. Am. J. Respir. Crit. Care Med. 1996; 154: 617–624.
   Google Scholar
• Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteraemia in an adult intensive care unit. Crit. Care Med. 1999; 27(8): 1421–1428.
   Google Scholar
• Crowe M, Ispahani P, Humphreys H, Kelley T. Bacteraemia in the Adult Intensive Care Unit of a Teaching Hospital in Nottingham UK. 1985-1996. Eur. J. Clin. MicrobioL Infect. Dis. 1998; 17: 377–384.
   Google Scholar
• Pittet D, Li N, Wenzel RP. Association of secondary and polymicrobial noscomial bloodstream infections with higher mortality. Eur. J. Clin. MicrobioL Infect. Dis. 1993; 12: 813–819.
   PubMed Web of Science ®Google Scholar
• Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch. Int. Med. 1995; 155: 1177–1184.
   Google Scholar
• Aliaga L, Mediavilla JD, Llosa J, Miranda C, Rosa-Fraile M. Clinical Significance of Polymicrobial Versus Monomicrobial Bacteraemia Involving Pseudomonas aeruginos.. Eur. J. Clin. MicrobioL Infect. Dis. 2000; 19: 871–874.
   Google Scholar
• Opal SM, Cohen J. Clinical Gram-positive sepsis: Does it fundamentally differ from Gram-negative bacterial sepsis. Crit. Care Med. 1999; 27(5): 1608–1616.
   PubMedGoogle Scholar
• Sriskandan S, Cohen J. Gram-positive sepsis: Mechanisms and Differences from Gram-negative Sepsis. Infect. Dis. Clin. N. Am. 1999; 13(2): 397–411.
   PubMed Web of Science ®Google Scholar
• Teti G. Septic shock caused by Gram-positive bacteria. Trends MicrobioL 1999; 7(3): 100–101.
   PubMedGoogle Scholar
• Verhoef J., Mattsson E. The role of cytokines in Gram-posi-tive bacterial shock. Trends MicrobioL 1995; 3(4): 136–140.
   PubMedGoogle Scholar
• Hessle C, Andersson B, Wold AE. Gram-Positive Bacteria Are Potent Inducers of Monocytic Interleukin-12 (IL-12) while Gram-Negative Bacteria Preferentially Stimulate IL-10 Production. Infect. Immun. 2000; 68(6): 3581–3586.
   Google Scholar
• Rabehi L, Irinopoulou T, Cholley B, Haeffner-Cavaillon N, Carreno M. Gram-Positive and Gram-Negative Bacteria Do Not Trigger Monocytic Cytokine Production through Simi-lar Intracellular Pathways. Infect. Immun. 2000; 69(7): 4590–4599.
   Google Scholar
• Barnham MRD, Weightman NC, Anderson AW, Tanna A. Streptococcal toxic shock syndrome: a description of 14 cases from North Yorkshire, UK. Clin. MicrobioL Infect. 2002; 8: 174–181.
   PubMed Web of Science ®Google Scholar
• Stevens DL., Tanner M H, Winshop J et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. New EngL J. Med. 1989; 321: 1–7.
   Google Scholar
• Cone L.A, Woodhard DR, Schlievert PM, Tomory GS. Clini-cal and bacteriological observations of a toxic shock-like syndrome due to streptococcus pyogenes. N. Engl. J. Med. 1987; 317: 146–149.
   Google Scholar
• Stevens DL. Invasive streptococcal infections. J. Infect. Chemother. 2001; 7:69–80.
   PubMedGoogle Scholar
• Hoge CW, Schwartz B, Talkington DF, Breiman RF„ MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of strep-tococcal toxic shock-like syndrome. A retrospective popu-lation-based study. JAMA 1993; 269: 384–389.
   Google Scholar
• Baxter F, McChesney J. Severe Group A Streptococcal Infec-tion and Streptococcal Toxic Shock Syndrome. Can. J. Anaes. 2001;47(11): 1129–1140.
   Web of Science ®Google Scholar
• Stevens DL. Streptococcal toxic shock syndrome. Clin. MicrobioL Infect. 2002; 8(3): 133–136.
   PubMed Web of Science ®Google Scholar
• Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Sta-phylococcus aureus. Clin. MicrobioL Rev. 2000; 13(1): 16–34.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. JAMA 1999; 282(12): 1123–1125.
   PubMed Web of Science ®Google Scholar
• Kaul R, Mcgeer A, Low DE et al. Population-based surveil-lance for group A streptococcal necrotizing fasciitis: clini-cal features, prognostic indicators and microbiological analysis of seventy-seven cases. Am. J. Med. 1997; 103: 18–24.
   PubMed Web of Science ®Google Scholar
• Sriskandan S, Moyes D, Cohen J. Detection of circulating bacterial superantigen and lymphotoxin-a in patients with streptococcal toxic-shock syndrome. Lancet 1996; 348: 1315–1316.
   Google Scholar
• Stevens DL. The flesh-eating bacterium: what‘s next? J. In-fect. Dis. 1999; 179\(supp 2): S366–S374.
   Google Scholar
• Lodise TP, Mckinnon PS, Tam V H, Rybak MJ. Clinical out-comes for patients with bacteraemia caused by vancomy-cin-resistant enterococcus in a level 1 trauma center. Clin. Infect. Dis. 2002; 34(7): 922–929.
   PubMed Web of Science ®Google Scholar
• Suppola JP, Kuikka A, Vaara M, Valtonen V. Comparison of Risk Factors and Outcome in Patients with Enterococcus faecalis versus Enterococcus faecium bacteraemia. Scand. J. Infect. Dis. 1998; 30: 153–157.
   PubMed Web of Science ®Google Scholar
• Georges H, Leroy 0, Vandenbussche C, et al. Epidemio-logical features and prognosis of severe community-ac-quired pneumococcal pneumonia. Intens. Care Med. 1999; 25: 198–206.
   Google Scholar
• Waterer GW, Wunderink RG. The influence of the severity of community acquired pneumonia on the usefulness of blood cultures. Resp. Med. 2001: 78–82.
   PubMed Web of Science ®Google Scholar
• Simpson JCG., Macfarlane JT, Watson J, Woodhead MA. A national confidential enquiry into community acquired pneu-monia in young adults in England and Wales. Thorax 2000; 55: 1040–1045.
   Google Scholar
• Macfarlane J. Severe pneumonia and a second antibiotic. Lancet 2002; 359: 1170–1171.
   PubMed Web of Science ®Google Scholar
• Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteraemic pneumococcal pneu-monia. Arch. Int. Med. 2001; 161: 1837–1842.
   PubMedGoogle Scholar
• Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcal aureus lower respiratory tract infections. Int. J. Antimicrobial Agents 2000; 16: S31–S34.
   PubMed Web of Science ®Google Scholar
• Fagon JY, Chastre J, Vuagnat A et al. Nosocomial pneumo-nia and mortality amoung patients in intensive care units. JAMA 1996; 275: 866–869.
   PubMed Web of Science ®Google Scholar
• Bodi M, Ardanuy C, Rello J. Impact of Gram-positive re-sistance on outcome of nosocomial pneumonia. Crit. Care. Med. 2001; 29(4): N82–N86.
   Google Scholar
• Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City Hospitals. Emerg. Infect. Dis. 1999; 5: 9–17.
   PubMed Web of Science ®Google Scholar
• Gonzales C, Rubio M, Romero-Vivas J. et al. Bacteraemic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin. Infect. Dis. 1999; 29: 1171–1177.
   Google Scholar
• Harrison L H, Pass MA, Mendelson AB, et al. Invasive menin-gococcal disease in adolescents and young adults. JAMA 2001; 286(8): 694–699.
   PubMedGoogle Scholar
• Durand ML, Calderwood SB, Weber DJ, et al. Acute bacte-rial meningitis in adults: a review of 493 episodes. N. EngL J. Med. 1997; 328: 328–329.
   Google Scholar
• Aubertin M, Porcher R, Bruneel F, et al. Pneumococcal Men-ingitis in the Intensive Care Unit. Prognostic factors of Clinical Outcome in a series of 80 cases. Am. J. Resp. Crit. Care Med. 2002; 165: 713–717.
   PubMed Web of Science ®Google Scholar
• Gins NI, Farid Z, Mickail IA, Farrag I, Sultan Y, Kilpatrick ME. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatr. Infect. Dis. 1989; 8: 848–851.
   Google Scholar
• Thomas R, Tulzo Y, Bouget J, et al. Trial of dexamethasone treatment for severe bacterial meningitis in adults. Int. Care Med. 1999; 25: 475–480.
   PubMed Web of Science ®Google Scholar
• Paris MM, Hickey SM, Uscher Ml, Shelton S, Olsen KD, McCracken GH Jr. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneu-mococcal meningitis. Antimicrob. Agents Chemother. 1994; 38(6): 1320–1324.
   PubMed Web of Science ®Google Scholar
• Gordon JJ, Harter DH, Phair JP. Meningitis due to Staphy-lococcus aureus. Am. J. Med. 1985; 78(1): 965–970.
   Google Scholar
• Jensen AG, Espersen F, Skinhoj P, Rosdahl VT, Frimodt-Moller N. Staphylocococcus aureus meningitis. A review of 104 nationwide, consecutive cases. Arch. Intern. Med. 1993; 23; 153(16): 1902 –1908.
   Google Scholar
• Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: its disease and toxins. Clin. MicrobioL Rev. 1998; 1: 1–18.
   Web of Science ®Google Scholar
• Kuijper EJ, de Weerdt J, Kato H, et al. Noscomial Outbreak of Clostridium difficile-Associated Diarrhoea due to a Clindamycin-Resistant Enterotoxin A-Negative Strain. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20: 528–534.
   PubMed Web of Science ®Google Scholar
• Nath SK, Thornley JH, Kelly M, et al. A sustained outbreak of Clostridium difficile in a general hospital: persistence of a toxigenic clone in four units. Infect. Control Hosp. EpidemioL 1994; 15(6): 382–389.
   PubMed Web of Science ®Google Scholar
• Samore M H, Bettin KM, DeGirolami PC, et al. Wide diver-sity of Clostridium difficile types at a tertiary referral hos-pital. J. Infect. Dis. 1994; 170(3): 615–621.
   PubMed Web of Science ®Google Scholar
• Madsen J M. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemi-cal-warfare agents. Clin. Lab. Med. 2001; 21(3): 593–605.
   Google Scholar
• Jackson PJ, Hugh-Jones ME, Adair DM et al. PCR analysis of tissue samples from the 1979 Sverdlovsk anthrax vic-tims: the presence of multiple Bacillus anthracis strains in different victims. Proc. Natl. Acad. Sci. USA 1998; 95: 1224–1229.
   PubMed Web of Science ®Google Scholar
• Shafazand S, Doyle R, Ruoss S, Weinacker A, Raffin TA. Inhalational Anthrax. Epidemiology, Diagnosis, and Man-agement. Chest 1999; 116:1369–1376.
   Google Scholar
• Swartz MN. Recognition and Management of Anthrax - An Update. N. EngL J. Med. 2001; 345: 1621–1626.
   PubMed Web of Science ®Google Scholar
• Roberts Al, Blumberg RS, Christ AD, Brolin RE, Ebert EC. Staphylococcal enterotoxin B induces potent cytotoxic ac-tivity by intraepithelial lymphocytes. Immunology 2000; 101: 185–190.
   Google Scholar
• Gerlach D, Schmidt K, Fleisher B. Basic streptococcal superantigens (SPEX/SMEZ or SPEC) are responsible for the mitogenic activity of the so-called mitogenic factor (MF). FEMS Immunol. Med. Micro. 2001; 30: 209–216.
   Google Scholar
• Hoe NP, Ireland RM, Deleo FR, et al. Insight into the mo-lecular basis of pathogen abundance: Group A Streptococ-cus inhibitor of complement inhibits bacterial adherence and internalisation into human cells. Proc. Natl. Acad. Sci. 1999; 11:7646–7651.
   Google Scholar
• Plitnick LM, Jordan RA, Banas JA, et al. Lipoteichoic Acid inhibits interleukin-2 (1L-2) function by direct binding to IL-2. Clin. Diag. Lab. ImmunoL 2001; 8(5): 972–979.
   PubMedGoogle Scholar
• Lemjabber H, Basbaum C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcal aureus in epithelial cells. Nature Med. 2002; 8(1): 41–46.
   PubMed Web of Science ®Google Scholar
• Underhill DM, Ozinsky A, Najjar AM, et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and dis-criminates between pathogens. Nature 1999; 401: 811–815.
   PubMed Web of Science ®Google Scholar
• Stuyt RJ, Netea MG, Kim S, et al. Differential Roles of Interleukin-18 (1L-18) and IL-12 for Induction of Gamma Interferon by Staphylococcal Cell Wall Components and Superantigens. Infect. Immun. 2001; 69(5): 5025–5030.
   PubMedGoogle Scholar
• Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Procl. Natl. Acad. Sci. 1995; 92: 10359–10363.
   PubMed Web of Science ®Google Scholar
• Kengatharan KM, Kimpe S, Robson C, Foster SJ, Thiemermann C. Mechanism of Gram-positive Shock: Iden-tification of Peptidoglycan and Lipoteichoic Acid Moieties Essential in the Induction of Nitric Oxide Synthase, Shock, and Multiple Organ Failure. J. Exp.. Med. 1998; 188(2): 305–315.
   Google Scholar
• Ginsburg. Role of lipoteichoic acid in infection and inflam-mation. Lancet Infect. Dis. 2002; 2(3): 171–179.
   Google Scholar
• Wang JE, Jorgensen PF, Almlof M, et al. Peptidoglycan and lipoteichoic acid from Staphylococcus areus induce tumour necrosis factor alpha, interleukin 6 (1L-6), and IL-10 pro-duction in both T cells and monocytes in a human whole blood model. Infect. Immun. 2000; 68(7): 3965–3970.
   PubMed Web of Science ®Google Scholar
• Cusumano V, Fera MT, Carbone M, Ciliberti A, Bellantoni A, Cusumano V. Synergic activities of streptococcal pyro-genic exotoxin A and lipoteichoic acid in cytokine induc-tion. New MicrobioL 2000; 23(1): 37–45.
   PubMedGoogle Scholar
• Dziarski R, Viriyakosol S, Kirkland TN, Gupta D. Soluble CD14 Enhances Membrane CD14-Mediated Responses to Peptidoglycan: Structural Requirements Differ from Those for Responses to Lipopolysaccharide. Infect. Immun. 2000; 68(9): 5254–5260.
   PubMed Web of Science ®Google Scholar
• Michel T, Reichhart J, Hoffman JA, Royet J. Drosophila Toll is activated by Gram-positive bacteria through a circulat-ing peptidoglycan recognition protein. Nature 2001; 414: 756–759.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Y, Yamakuchi M, et al. Upregulation of Toll-like Receptor 2 Gene Expression in Macrophage Response to Peptidoglycan and High Concentration of Lipopolysac-charide Is Involved in NF-kB Activation. Infect. Immun. 2001; 69(5): 2788–2796.
   PubMed Web of Science ®Google Scholar
• Dziarski R, Wang Q, Miyake K, Kirschning CJ, Gupta D. MD-2 Enables Toll-Like Receptor 2 (TLR2)-Mediated Re-sponses to Lipopolysaccharide and Enhances TLR2-Medi-ated Responses to Gram-Positive and Gram-Negative Bac-teria and Their Cell Wall Components. J. Immunol. 2001; 166: 1938–1944.
   Google Scholar
• Wang Q, Dziarski R, Kirsching CJ, Muzio M, Gupta D. Micrococci and Peptidoglycan Activate TLR2-MyD88-IRAK-TRAF-NIK-NF-kB Signal Transduction Pathway That Induces Transcription of Interleukin-8. Infect. ImmunoL 2001; 69(4): 2270–2276.
   Google Scholar
• Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A Novel Polymorphism in the Toll-Like Receptor 2 Gene and Its Potential Association with Staphylococcal Infec-tion. Infect. Immun. 68(11): 6398–6401.
   Google Scholar
• Henneke P, Takeuchi 0, van Strijp JA, et al. Novel Engage-ment of CD14 and Multiple Toll-like Receptors by Group B Streptococci. J. ImmunoL 2001; 167: 7069–7076.
   Google Scholar
• Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and ia a crucial mediator of sep-tic shock. Nature 2001; 410: 1103–1107.
   PubMed Web of Science ®Google Scholar
• Calandra T, Spiegal LA, Metz ON, Bucala R. Macrophage migration inhibitory factor is a critical mediator of the acti-vation of immune cells by exotoxins of Gram-positive bac-teria. Proc. Natl. Acad. Sci. 1998; 95: 11383–11388.
   PubMed Web of Science ®Google Scholar
• Paton JO, Andrew PW, Boulnois GJ, Mitchell TJ. Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins. Ann. Rev. Microbiol. 1993; 47: 89–115.
   PubMed Web of Science ®Google Scholar
• Braun JS, Novak R, Gao G, Murray PJ, Shenep JL. Pneumolysin, a protein toxin of Streptococcus pneumoniae, induces nitric oxide production from macrophages. Infect. Immun. 1999; 67(8): 3750–3756.
   Google Scholar
• Madden JC, Ruiz N, Caparon M. Cytolysin-Mediated Trans-location (CMT): A Functional Equivalent of Type III Secre-tion in Gram-Positive Bacteria. Cell 2001; 104:143–152.
   Google Scholar
• Doran KS, Chang JC, Benoit VM, Eckmann L, Nizet V. Group B streptococcal beta-hemolysin/cytolysin promotes invasion of human lung epithelial cells and the release of interleukin-8. J. Infect. Dis. 2002; 185(2): 196–203.
   Google Scholar
• Kapur V, Topouzis S, Majesky MW, et al. A conserved Streptococcus pyogenes extrace II u la r cysteine protease cleaves human fibronectin and degrades vitronectin. Microb. Pathog. 1993; 15: 327–346.
   PubMed Web of Science ®Google Scholar
• Kapur V, Majeski MW, Li LL, Black RA, Musser JM. Cleav-age of interleukin lb precursor to produce active IL-lb by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc. Natl. Acad. Sci. USA 1993; 90: 7676–7680.
   Google Scholar
• Sriskandan S, Cohen J. Kallikrein-Kinin System Activation in Streptococcal Toxic Shock Syndrome. Clin. Infect. Dis. 2000; 30: 961–962.
   PubMed Web of Science ®Google Scholar
• Herwald H, Colin M, Muller-Esterl W, Bjork L. Streptococ-cal cysteine proteinase releases kinins: a novel virulence mechanism. J. Exp. Med. 1996; 184: 665–673.
   Google Scholar
• Watanabe Y, Todome Y, Ohkuni H, et al. Cysteine Protease Activity and Histamine Release from the human mast cell line H MC-1 stimulated by recombinant streptococcal pyro-genic exotoxin B/Streptococcal Cysteine Protease. Infect. Immun. 2002; 70(7): 3944–3947.
   PubMed Web of Science ®Google Scholar
• Mattisson E, Herwald H, Cramer H, Persson K, Sjobring U, Bjorck L. Staphylococcal aureus Induces Release of Bradyki-nin in Human Plasma. Infect. Immunol. 2001; 69(6): 3877–3882.
   PubMed Web of Science ®Google Scholar
• Ashbaugh CD, Wessels MR. Abscence of a Cysteine Pro-tease Effect on Bacterial Virulence in Two Murine Models of Human Invasive Group A Streptococcal Infection. Infect. Immun. 2001; 69(11): 6683–6686.
   PubMed Web of Science ®Google Scholar
• Kum WS, Cameron SB, Hung RWY, Kalyan S, Chow AW. Temporal Sequence and Kinetics of Proinflammatory and Anti-inflammatory Cytokine Secretion Induced by Toxic Shock Syndrome Toxin 1 in Human Peripheral Blood Mono-nuclear cells. Infect. Immun. 2001; 69(12): 7544–7549.
   Google Scholar
• Sperber K, Silverstein L, Brusco C,Yoon C, Mullin GE, Mayer L. Cytokine Secretion Induced by Superantigens in Periph-eral Blood Mononuclear Cells, Lamina Propria Lymphocytes, and Intraepithelial Lymphocytes. Clin. Diag. Lab. Immunol. 1999; 2(4): 473–477.
   Google Scholar
• Llewelyn M., Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect. Dis. 2002; 2(3): 156–162.
   PubMed Web of Science ®Google Scholar
• Fraser J., Arcus V., Kong P., Baker E., Proft T. Superantigens-powerful modifiers of the immune system. MoL Med. To-day; 2000; 6: 125–132.
   Google Scholar
• Tiedmann R.E., Fraser J.D. Cross-linking of MHC class ll molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T-cell activation. J. Immunol. 1996; 157(9): 3958–3966.
   PubMed Web of Science ®Google Scholar
• Mehindate K., Thibodeau J., Dohlston M., Kalland T., Sekaly R.P., Mourad W. Cross-linking of major histocompatability complex class ll molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J. Exp. Med. 1995; 182(5): 1573–1577.
   PubMed Web of Science ®Google Scholar
• Proft T, Moffat SL, Berkahn CJ, Fraser JD. Identification and characterization of novel superantigens from Strepto-coccus pyogenes. J. Exp. Med. 1999; 189(1): 89–102.
   PubMed Web of Science ®Google Scholar
• Proft T, Moffat SL, Weller KD, Paterson A, Martin D, Fraser JD. The streptococcal superantigen SMEZ exhibits wide al-lelic variation, mosaic structure and significant antigenic variation. J. Exp. Med. 2000; 1(10): 1765–1776.
   Google Scholar
• Schumann J. Synergism of Pseudomonas aeruginosa exotoxin A with endotoxin, superantigen or TNF results in TNFR1-and TNFR2-dependent liver toxicity in mice. Immunol. Lett. 2000; 74: 165–172.
   PubMed Web of Science ®Google Scholar
• Blank C, Luz A, Bendigs S, Erdmann S, Wagner H. Superantigen and endotoxin synergize in the induction of lethal shock. Eur. J. ImmunoL 1997; 27: 825–833.
   Google Scholar
• Parsonnet J, Gillis ZA. Production of Tumour Necrosis Fac-tor by human Monocytes in response to toxic shock syn-drome toxin 1. J. Infect. Dis. 1988; 158(5): 1026–1033.
   PubMed Web of Science ®Google Scholar
• Luhm J, Kirchner H, Rink L. One-way synergistic effect of low superantigen concentrations on lipopolysaccharide-in-duced cytokine production. J. Intelfer. Cyt. Res. 1997; 17: 229–238.
   Google Scholar
• Dinges MM, Schlievert PM. Role of T cells and Gamma interferon during induction of hypersensitivity to lipopoly-saccharide by Toxic Shock Syndrome Toxin 1 in Mice. Infect. Immunol. 2001; 69(3); 1256–1264.
   Google Scholar
• Vella A, McCormack JE, Linsley PS, Kappler JW, Marrack P. Lipopolysaccharide interferes with the induction of pe-ripheral T cell death. Immunity 1995; 2(3): 261–270.
   Google Scholar
• Hochholzer P, Grayson LB, Wagner H, Pfeffer K, Heeg K. Role of Interleukin-18 (I L-18) during Lethal Shock: Decreased Lipopolysaccharide Sensitivity but Normal Superantigen Reaction in IL-18-Deficient Mice. Infect. Immunol. 2000; 68(6): 3502–3508.
   Google Scholar
• Dunne WM. Bacterial Adhesion: Seen Any Good Biofilms Lately? Clin. MicrobioL Rev. 2002; 15(2): 155–166.
   Google Scholar
• Donlan RM, Costerton JW. Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms. Clin. MicrobioL Rev. 2002; 15(2): 167–193.
   PubMed Web of Science ®Google Scholar
• Ziebuhr W, Helimann C, Gotz F, et al. Detection of the inter-cellular adhesion gene cluster (ica) and phase variation in S. epidermidis blood culture strains and mucosa isolates. In-fect. Immunol. 1997; 65: 890–896.
   Google Scholar
• de Silva G DI, Kantzanou M, Justice A, et al. The ica Operon and Biofilm Production in Coagulase-Negative Staphylo-cocci Associated with Carriage and Disease in a Neonatal Intensive Care Unit. J. Clin. MicrobioL 2002; 40(2): 382–388.
   PubMed Web of Science ®Google Scholar
• Shiau AL, Wu CL. The inhibitory effect of S. epidermidis slime on the phagocytosis of murine peritoneal macrophages is interferon-independent. MicrobioL ImmunoL 1998; 42: 33–40.
   Google Scholar
• Jones SM, Morgan M, Humphrey TJ, Lappin-Scott H. Ef fect of vancomycin and rifampicin on methicillin-resistant Staphylococcus aureus biofilms. Lancet 2001; 357: 40–41.
   Google Scholar
• O'Gara JP, Humphreys H. Staphylococus epidermidis biofilms: importance and implications. J. Med. MicrobioL 2001; 50(7): 582–587.
   Google Scholar
• Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A compo-nent of innate immunity prevents bacterial biofilm devel-opment. Nature 2002; 417: 552–555.
   PubMed Web of Science ®Google Scholar
• Guillen C., McInnes IB., Vaughan DM, et al. Enhanced Th 1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. J. ImmunoL 2002; 168(8): 3950–3957.
   PubMed Web of Science ®Google Scholar
• Miwa K, Fukuyama M, Igarashi H. Rapid assay for detec-tion of toxic shock syndrome toxin 1 from human sera. J. Clin. MicrobioL 1994; 32(2): 539–542.
   Google Scholar
• Pitt TL, Saunders NA. Molecular bacteriology: a diagnostic tool for the millennium. J. Clin. PathoL 2000; 53: 71–75.
   PubMed Web of Science ®Google Scholar
• Fluit AC, Visser MR, Schmitz F. Molecular Detection of Antimicrobial Resistance. Clin. MicrobioL Rev. 2001; 14(4): 836–871.
   PubMed Web of Science ®Google Scholar
• Cursons RT, Jeyerajah E, Sleigh JW. The use of polymerase chain reaction to detect septicaemia in critically ill patients. Crit. Care Med. 1999; 27(5): 860–861.
   Google Scholar
• Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. EngL J. Med. 2001; 345(19): 1368–1377.
   PubMed Web of Science ®Google Scholar
• Weinstein RA. Controlling antimicrobial resistance: The role of infection control and antimicrobial use. In: Program of the 4th Decennial International Conference on Noscomial and Healthcare-Associated Infections. Atlanta, Centers for Disease Control and Prevention, March 5–9; 2000: 7.
   Google Scholar
• Austin DJ, Bonten MJM, Weinstein RA, Slaughter S, Anderson RM. Vancomycin-resistant enterococci in inten-sive-care hospital settings: Transmission dynamics, persistence and the impact of infection control programs. Proc. NatL Acad. Sci. 1999; 96: 6908–6913.
   Google Scholar
• von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacterae- m i a. N. Engl. J. Med. 2001; 344(1): 11–16.
   Google Scholar
• Kluytmans JA, Mouton JW, Ljzerman EPF et al. Nasal car-riage of Staphylococcal aureus as a major risk factorfor wound infections after cardiac surgery. J. Infect. Dis. 1995; 171: 216–219.
   PubMed Web of Science ®Google Scholar
• Schentag JJ. Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit. Crit. Care Med. 2001; 29(4): N100–N107.
   PubMed Web of Science ®Google Scholar
• Schentag JJ., Hyatt JM, Carr JR et al. Genesis of methicillin-resistant Staphylococcal aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant En-terococcus faecium, and the importance of antibiotic manage-ment and infection control. Clin. Infect. Dis. 1998 26: 1204–1214.
   Google Scholar
• Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit. Care Med. 2001; 29(6): 1101–1108.
   PubMed Web of Science ®Google Scholar
• Ginzburg E, Namias N, Brown M, Ball S. Hameed SM, Cohn SM. Gram positive infection in trauma patients: new strategies to decrease emerging Gram-positive resistance and vancomycin toxicity. Int. J. Antimicrobial Agents 2000; 16: S39–S42.
   PubMed Web of Science ®Google Scholar
• John JF Jr. Antibiotic cycling: is it ready for prime time? [editorial]. Infect. Control Hosp. EpidemioL 2000; 21: 9–11.
   PubMed Web of Science ®Google Scholar
• Shankar N, Baghdayan AS, Gilmore MS. Modulation of virulence within a pathogenicity island in vancomycin-re-sistant Enterococcus faecalis. Nature 2002; 417: 746–750.
   Google Scholar
• di Filippo A, De Gaudio AR, Novelli A, et al. Continuous infusion of vancomycin in methicillin-resistant staphyloco-ccus infection. Chemotherapy 1998; 44(1): 63–68.
   PubMed Web of Science ®Google Scholar
• Garcia MS, Galache JAC, Diaz JL et al. Effectiveness and Cost of Selective Decontamination of the Digestive Tract in Critically ill Intubated Patients. Am. J. Respir. Crit. Care Med. 1998; 158: 908–916.
   PubMed Web of Science ®Google Scholar
• Nardi G, Silvestre TD, De Monte A, et al. Reduction in Gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin. Eur. J. Emerg. Med. 2001; 8(3): 203–214.
   PubMedGoogle Scholar
• D'Amico R, Pifferi S, Leonetti C, Torn i V, Tinazzi A, Liberati A. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomized control-led trials. BMJ 1998; 316: 1275–1285.
   Google Scholar
• Hammond JMJ, Potgieter PD. Long-term effect of selective decontamination on microbial resistance. Crit. Care Med. 1995; 23: 637–645.
   PubMed Web of Science ®Google Scholar
• Ebner W, Kropec- Hubner A, Dashner FD. Bacterial Resist-ance and Overgrowth due to Selective Decontamination of the Digestive Tract. Eur. J. Clin. Microbiol. Infect. Dis. 2000; 19: 243–247.
   PubMed Web of Science ®Google Scholar
• Lingnau W, Berger J, Javorsky F, Fille M, Allerberger F, Benzer H. Changing bacterial ecology during a five year period of selective intestinal decontamination. J. Hosp. In-fect. 1998; 39: 195–206.
   PubMed Web of Science ®Google Scholar
• Verwaest C, Verbist L, Lauwers P. Randomised, controlled trial of selective digestive decontamination in 600 mechani-cally ventilated patients in a multidisciplinary intensive care unit. Crit. Care Med. 1997; 25: 63–71.
   Google Scholar
• Stevens DL, Bryant E, Hackett SP. Antibiotic effects on bacterial viability, toxin production and host response. Clin. Infect. Dis. 1995; 20\(Supp 2): S154–157.
   Google Scholar
• Gao JJ, Zuvanich EG, Xue Q, Horn DL, Silverstein R, Morrison DC. Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J. Immunol. 1999; 163: 4095–4099.
   Google Scholar
• Hacker G, Redecke V, Hacker H. Activation of the immune system by bacterial CpG-DNA. Immunology 2002; 105: 245–251.
   Google Scholar
• Holzheimer RG. The significance of endotoxin release in experimental and clinical sepsis in surgical patients-evi-dence for antibiotic-induced endotoxin release? Infection 1998; 26(2): 77–84
   PubMed Web of Science ®Google Scholar
• Nau R, Eiffert H. Modulation of Release of Proinflammatory Bacterial Componds by Antibacterials: Potential Impact on Course of Inflammation and Outcome in Sepsis and Meningitis. Clin. MicrobioL Rev. 2002; 15(1): 95–110.
   PubMed Web of Science ®Google Scholar
• Mattsson E, Van Dijk H, Verhoef J, Norrby R, Rollof J. Supernatants from S. epidermidis grown in the presence of different antibiotics induce differential release of tumour necrosis factor alpha from human monocytes. Infect. Immun. 1996; 164: 4351–4355.
   Google Scholar
• van Langeveld P, Ravensbergen E, Grashoff P, Beckhuizen H, Groeneveld PH, van Dissel JT. Antibiotic-induced cell wall fragments of S. aureus increase endothelial chemokine secretion and adhesiveness for granulocytes. Antimicrob. Agents Chemother. 1999; 43: 2984–2989.
   Google Scholar
• Cohen J. Adjuvant therapy in sepsis: A critical analysis of the clinical trial programme. Br. Med. Bull. 1999; 55: 212–225.
   PubMed Web of Science ®Google Scholar
• Ziegler EJ, Fischer CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteraemia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomised, double blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. EngL J. Med. 1991; 324(7): 429–436.
   Google Scholar
• McCormick JK, Tripp TJ, Olmsted SB, et al. Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J. ImmunoL 2000; 165(4): 2306–2312.
   PubMed Web of Science ®Google Scholar
• Roggiani M, Stoehr JA, Olmsted SB, Matsuka YV, Pillai S, Ohlendorf D H. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect. Immun. 2000; 68(9): 5011–5017.
   Google Scholar
• Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. Con-tinuous infusion of ceftazidime in intensive care: a randomized controlled trial. J. Antimicrob. Chemother. 1999; 43: 309–311.
   Google Scholar
• Arad G, Levy R, Hillman D, Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nature Med. 2000; 6(4): 414–421.
   PubMed Web of Science ®Google Scholar
• Vincent Collins L, Eriksson K, Ulrich RG, Tarkowski A. Mucosal tolerance to a bacterial superantigen indicates a novel pathway to prevent toxic shock. Infect. Immun. 2002; 70(5): 282–2287.
   Google Scholar
• Patel R, Rouse MS, Florez MV, et al. Lack of Benefit of Intravenous Immune Globulin in a Murine Model of Group A Streptococcal Necrotizing Fasciitis. J. Infect. Dis. 2000; 181:230–234.
   PubMed Web of Science ®Google Scholar
• Werdan K. Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr. Opin. Crit. Care 2001; 7(5): 354–361.
   PubMedGoogle Scholar
• Schlievert PM. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J. Allergy Clin. Immunol. 2001; 108: S107–S110.
   PubMed Web of Science ®Google Scholar
• Fronhoffs S, Luyken J, Steuer K, Hansis M, Vetter H, Walger P. The effect of C1-esterase inhibitor in definite and sus-pected streptococcal toxic shock syndrome. Report of seven patients. Int. Care Med. 2000; 26: 1566–1570.
   PubMed Web of Science ®Google Scholar
• Saetre T, Hoiby EA, Aspelin T, Lermark G, Egeland T, Lyberg T. Aminoethyl-isothiourea, a nitric oxide synthase inhibitor and oxygen radical scavinger, improves survival and counteracts haemodynamic deterioration in a porcine model of streptococcal shock. Crit. Care Med. 2000; 28(8): 2697–2706.
   PubMed Web of Science ®Google Scholar
• Sriskandan S, Moyes D, Buttery LK et al. The role of nitric oxide in experimental murine sepsis due to pyogenic exo-toxin A-producing Streptococcus pyogenes. Infect. Immunol. 1997; 65: 1767–1772.
   PubMed Web of Science ®Google Scholar
• Bannan JD, Mingo F, Viteri. Neutralization of streptococcal pyrogenic exotoxins and staphylococcal enterotoxins by an-tiserum to synthetic peptides representing conserved amino acid motifs. Adv. Exp. Med. Biol. 1997; 418: 903–907.
   Google Scholar
• Campbell DE, Georgiou GM, Kemp AS. Pooled Human Immunoglobulin Inhibits IL-4 but not IFN-g or TNF-a se-cretion Following In Vitro Stimulation Of Mononuclear Cells With Staphylococcal Superantigen. Cytokine 1999; 11(5): 359–365.
   Google Scholar
• Scott MG, Gold MR, Hancock REW. Interaction of Cationic Peptides with Lipoteicoic Acid and Gram-Positive Bacte-ria. Infect. Immunol. 1999; 67(12): 6445–6453.
   Google Scholar
• Kaul R, McGeer A, Norrby-Teglund A, Kobt M, Schwartz B, O'Rourke K. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome- a comparative obser-vational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis. 1999; 28(4): 800–807.
   Google Scholar
• Hale ML, Margolin SB, Krakauer T, Roy CJ, Stiles BG. Pirfenidone blocks the in vitro and in vivo effects of Staphy-lococcal enterotoxin B. Infect. Immunol. 2002; 70(6): 2989–2994.
   PubMed Web of Science ®Google Scholar
• Shupp JW, Jett M, Pontzer CH. Identification of a transcytosis epitope on Staphylococcal enterotoxins. Infect. Immunol. 2002; 70(4): 2178–2186.
   Google Scholar
• Shinefield H, Black S, Fattom A, et al. Use of a Staphylococus qureus conjugate vaccine in patients receiving hemodialysis. N. EngL J. Med. 346(7): 491–496.
   Google Scholar
• Daum RS, Seal JB. Evolving antimicrobial chemotherapy for Staphylococcus aureus infections: Our backs to the wall. Crit. Care Med. 2001; 29(4): supp: N92–N96.
   Google Scholar
• Loeffler JM, Nelson D, Fischetti VA. Rapid Killing of Strep-tococcus pneumoniae with a Bacteriophage Cell Wall Hydro-lase. Science 2001; 294:2170–2172.
   Google Scholar
• Nelson D, Loomis L, Fischetti VA. Prevention and elimina-tion of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. 2001; 98(7): 4107–4112.
   Google Scholar
• Biswas B, Adhya S, Washaert P, et al. Bacteriophage therapy rescues mice bacteraemic from a clinical isolate of Vanco-mycin-resistant Enterococcus faecium. Infect. Immunol. 2002; 70(1): 204–210.
   PubMed Web of Science ®Google Scholar
• Steidler L et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352–1355.
   PubMed Web of Science ®Google Scholar
• Reid G, Howard J, Gan BS. Can bacterial interference pre-vent infection? Trends Microbiol. 2001; 9(9): 424–428.
   Google Scholar
• Ji G. et al. Bacterial interference caused by autoinducing peptide variants. Science 1997; 276:27–2030. Care Med. 2001; 29(6); 1101-1108.
   PubMedGoogle Scholar
• Scharfman WB, Tillotson JR, Taft EG, Wright E. Plas-mapheresis for meningococcaemia with disseminated in-travascular coagulation. New EngL J. Med. 1979; 300: 1277–1278.
   PubMed Web of Science ®Google Scholar
• MM Hoeper, Abou-Rebyeh F, Athman C, Schwarz A. Plas-mapheresis in Streptococcal Toxic Shock Syndrome. Crit. Care Med. 2001; 29: 2399.
   PubMed Web of Science ®Google Scholar
• Cole L, Bellomo R, Hart G, et al. A phase ll randomised, controlled trial of continuous hemofiltration in sepsis. Crit. Care Med. 2002; 30(1): 100–106.
   PubMed Web of Science ®Google Scholar
• Murray BE. Vancomycin-resistant enterococcal infections. New EngL J. Med. 2000; 342: 710–721.
   Google Scholar
• Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treat-ment for invasive Streptococcus pyogenes infection. Pediatr. Infect. Dis. J. 1999; 18: 1096–1100.
   Google Scholar
• Fluit AC, Wielders CLC, Verhoeff J, Schmitz FJ. Epidemi ology and susceptibilty of 3,051 Staphylococus aureus iso-lates from 25 university hospitals participating in the Euro-pean SENTRY Study. J. Clin. Microbiol. 2001; 39(10): 3727–3732.
   PubMed Web of Science ®Google Scholar
• Sriskandan S, McKee A, Hall L, Cohen J. Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J. Anti microb. Chemother. 1997; 40(2): 275–277.
   PubMed Web of Science ®Google Scholar
• Ricaurte JC, Boucher HW, Tyrett GS, Moellering RC, LaBombardi VJ, Kislak JW. Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteraemia. Clin. Microbial. Infect. 2001; 7: 17–21.
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant enterococci. Clin. In-fect. Dis. 1998; 27: 1259–1265.
   PubMed Web of Science ®Google Scholar
• Wareham DW, Wilson P. Chloramphenicol in the 21st cen-tury. Hosp. Med. 2002; 63(3): 157–161.
   PubMed Web of Science ®Google Scholar
• Guerin F, Buu-hoi A, Mainardi J. Outbreak of methicillin-resistant S. aureus with reduced susceptibility to glycopeptides in a Paris hospital. J. Clin. Microbiol. 2000; 38: 2985–2988.
   Google Scholar
• Dowzicky M, Nadler HL, Ferger C et al. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am. J. Med. 1998; 104: 34S–42S.
   Google Scholar
• Fagon J, Patrick H, Haas DW et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomy-cin. Noscomial Pneumonia Group. Am. J. Respir. Crit. Care Med. 2000; 161: 753–762.
   Google Scholar
• Tally FP, Michael Z, Wasilewski MM et al. Daptomycin : a novel agent for Gram-positive infections. Exp. Opin. Inves. Drugs 1999; 8: 1223–1238.
   PubMedGoogle Scholar
• Bonten MJ, Willems R, Weinstein RA. Vancomycin-resist-ant enterococci: why are they here, and where do they come from? Lancet Infect. Dis. 2001; 1(5): 314–325.
   Google Scholar
• Paris MM, Ramilo 0, McCracken GH Jr. Minireview: man-agement of meningitis caused by penicillin-resistant Strep-tococcus pneumoniae. Antimicrob. Agents Chemother. 1995; 39(10): 2171–2175.
   PubMedGoogle Scholar
• Verbist L. The antimicrobial activity of fusidic acid. J. Antimicrob. Chemother. 1990; 25(supp): 1–5.
   Google Scholar
• Chang S-C, Hsieh S, Chen M, Sheng W, Chen Y. Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aurues colonization and results in emergence of fusidic acid-resistant strains. Diag. Microbiol. Infect. Dis. 2000; 36: 131–136.
   Google Scholar
• Fridkin SK, Edwards JR, Courval JM et al. Intensive care antimicrobial resistance epidemiology (ICARE) project and the National Nosocomial Infections Surveillance System (NNIS) hospitals. The effect of vancomycin and third-gen-eration cephalosporins on prevalence of vancomycin-resist-ant enterococci in 126 US adult intensive care units. Ann. Intern. Med. 2001; 135(3): 175–183.
   Google Scholar
• Chow JW. Aminoglycoside resistance in enterococci. Clin. Infect. Dis. 2000; 31: 586–589.
   PubMed Web of Science ®Google Scholar
• Zwaveling JH, Maring JK, Klompmaker et al. Selective de-contamination of the digestive tract to prevent postopera-tive infection: a randomised placebo-controlled trial in liver transplant patients. Crit. Care Med. 2002; 30(6); 1204–1209.
   Google Scholar